期刊文献+

重组腺病毒介导hPSMA和4-1BBL基因转染小鼠树突状细胞的变化及临床意义 被引量:3

The Change and Clinical Significance of Recombinant Adenovirus Mediated Mouse HPSMA and 4-1BBL Gene Transfection of Dendritic Cells
原文传递
导出
摘要 目的:研究hPSMA和4-1BBL基因转染小鼠树突状细胞(DC)后的变化及其在前列腺癌方面的临床意义。方法:以含hPSMA和4-1BBL基因的重组腺病毒载体转染C57BL/6j小鼠骨髓来源的DC,将培养的DC分为阳性组(Ad/hPSMA-IRES-m4-1BBL组)、阴性对照组(Ad5LacZ组)和未转染组,分别加入重组腺病毒、空载质粒腺病毒和生理盐水后,采用流式细胞仪测定腺病毒的转染效率;用相差显微镜、扫描电镜和透视电镜观察DC的形态学变化;用流式细胞仪分析表型变化;用Western blot检测DC hPSMA蛋白的表达。结果:经体外诱导培养后获得的树突状细胞在相差显微镜、透视电镜和扫描电镜下均观察到具有典型形态的成熟DC;流式细胞仪检测腺病毒转染效率为70%,Ad/hPSMA-IRES-m4-1BBL组DC细胞表面MHC-Ⅱ、CD80、CD86较其余两组无明显差异(P>0.05),但4-1BBL有明显提高(P<0.05);Western blot检测DC蛋白表达出PSMA。结论:本实验中获得的DC具有成熟DC的典型特征,DC表面的4-1BBL表达率明显上调,表达出PSMA蛋白。本研究将为DC应用于前列腺癌的生物治疗奠定基础。 Objective:To investigate the changes of the dendritic cell (DC) which was transfected by hPSMA and 4-1BBL genes as well as their clinic significance in prostate cancer. Methods: Using the recombinant adenovirus vector containing hPSMA and 4-1BBL genes to transfect the dendritic cells which were from C57BL/6j mouse bone marrow. Allocating the dendritic cells for three groups: positive group(Ad/hPSMA-IRES-m4- 1BBL group), negative group (AdSLacZ group) and in transfected group, we added the recombinant adenovirus, the empty vector of adenovirus and physiological saline in groups respectively. And then detected the efficiency of adenovirus transfection efficiency by FACS and observing the morphologic changes of the dendritic cells under the phase contrast microscope, the scanning transmission electron micrographs and the transmission electron micrographs; the surface molecular expression of DCs were detected by FACS; At last, detection of expression of protein of hPSMA of DCs by Western blot. Results: The induced DCs in vitro displayed the typical morphological characteristics of mature DCs under the phase contrast microscope, the scanning transmission and the transmission electron micrographs. 70% of adenovirus transfected efficiency was reported by FACS. It is no obvious difference between the group of Ad/hPSMA-IRES-m4-1BBL and the other two groups(P〉0.05)in MHC-II , CD80 and CD86 of the surface of DCs. But the 4-1BBL which was one of the surface of DCs was increased(P〈0.05). Conclusions: The obtained DCs displayed the typical morphological characteristics of mature DC, the rate of 4-1BBL expression of surface DC was obviously up-regulated and DCs expressed the protein of PSMA. This study would build theoretic basis for DIE biological treatment of prostate cancer.
出处 《临床泌尿外科杂志》 北大核心 2010年第3期230-234,共5页 Journal of Clinical Urology
基金 国家自然科学基金(编号30672107)
关键词 树突状细胞 hPSMA基因 4-1BBL基因 变化 dendritic cell hPSMA genes 4-1BBL genes change
  • 相关文献

参考文献15

  • 1Srivastava R M,Khar A.Dendritic cells and their receptors in antitumor immune response[J].Curr Mol Med,2009,9(6):708-724.
  • 2Smits E L,Anguille S,Cools N,et al.Dendritic cellbased cancer gene therapy[J].Hum Gene Ther,2009,20(10):1106-1118.
  • 3Akbar S M,Horiike N,Onji M,et al.Dendritic cells and chronic hepatitis virus carriers[J].Interviol,2001,44(4):199-208.
  • 4Arlen P M,Gulley J L.Therapeutic vaccines for prostate cancer:a review of clinical data[J].Curr Opin Investig Drugs,2005,6(6):592-596.
  • 5Pirtskhalaishvili G,Shurin G V,Gambotto A,et al.Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice[J].J Immunol,2000,165(4):1956-1964.
  • 6Kobie J J,Wu R S,Kurt R A,et al.Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines[J].Cancer Res,2003,63(8):1860-1864.
  • 7Chulso Moon,Jong Chul Park,Young Kwang Chae,et al.Current status of experimental therapeutics for prostate cancer[J].Cancer Letters,2008,266 (2):116-134.
  • 8汪波,曹开源,徐向东,徐霖,袁广卿,张甜,丘少鹏.PSMA基因疫苗抑瘤效应及免疫机制的实验研究[J].中国病理生理杂志,2009,25(1):118-122. 被引量:4
  • 9Croft M.Co-stimulatory members of the TNFR family:keys to effective T-cell immunity?[J].Nat Rev Immunol,2003,3(8):609-620.
  • 10Rabu C,Quemener A,Jacques Y,et al.Production of recombinant human trimeric CD137L (4-1BBL).Crosslinking is essential to its T-cell co-stimulation activity[J].J Biol Chem,2005,280(50):41472-41481.

二级参考文献11

  • 1康鲁东,吴伟芳,崔福爱,王秀利,胡晓燕,孔峰.人前列腺特异性膜抗原基因启动子/增强子表达载体的构建及组织特异性鉴定[J].中国病理生理杂志,2007,23(1):120-123. 被引量:4
  • 2Jin F, Xie Z, Kuo C J, et al. Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus - mediated antiangiogenesis and oncolysis combination therapy [ J]. Cancer Gene Ther, 2005,12(3) :257 - 267.
  • 3Satoh T, Teh BS, Timme TL, et al. Enhanced systemic T - cell activation after in situ gene therapy with radiotherapy in prostate cancer patients[ J]. Int J Radiat Oncol Biol Phys, 2004,59(2) :562 -571.
  • 4Srivastava IK, Liu MA. Gene vaccines [ J ]. Ann Intern Med, 2003,138(7) :550-559.
  • 5Qin H, Zhou C, Wang D, et al. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens [ J ]. Immunol Lett, 2005,99 (1) :85 -93.
  • 6Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients [ J ]. Anticancer Res, 1987,7(5B) :927 -935.
  • 7Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostate - specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease[J]. Cancer Res, 2001,61 (16) :6029 - 60331
  • 8Birtle AJ, Freeman A, Masters JR, et al. Tumour markers for managing men who present with metastatic prostate cancer and serum prostate - specific antigen levels of < 10 ng/mL[ J ]. BJU Int, 2005,96 (3) : 303 - 307.
  • 9Marchal C, Redondo M, Padilla M, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[ J]. Histol Histopathol, 2004,19 (3) :715 - 718.
  • 10Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate - specific membrane antigen expression with disease recurrence in prostate cancer [ J ]. Clin Cancer Res, 2003,9(17) :6357 -6362.

共引文献3

同被引文献7

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部